

# The future of hemophilia A treatment: From Jivi® to gene therapy

EAHAD 2020 Congress | The Hague, Netherlands  
Wednesday, February 5 | 13:45–15:00 | Mississippi Room, World Forum

Join us for a review of the latest Jivi® (damoctocog alfa pegol) data from the PROTECT VIII study; learn about breaking head-to-head data; and explore the first clinical data from Bayer's gene therapy, BAY 2599023.

TOPIC	SPEAKER
Foundation for the future: Setting the standard in hemophilia A with rFVIII	Robert Klamroth (chair) <i>Vivantes Klinikum im Friedrichshain, Germany</i>
PEGylation and PK: The science behind Jivi®	Diego Fornasari <i>University of Milan, Italy</i>
6 years of experience with Jivi®: PROTECT VIII	Mark Reding <i>University of Minnesota, USA</i>
Jivi® in clinical practice: Real-world evidence and the patient perspective	Jonathan Ducore <i>UC Davis Children's Hospital, USA</i>
	Natascha Marquardt <i>Universitätsklinikum Bonn, Germany</i>
Gene therapy: The ultimate innovation for patients	Steve Pipe <i>University of Michigan, USA</i>
Wrap-up and close	Robert Klamroth <i>Vivantes Klinikum im Friedrichshain, Germany</i>



Recombinant Factor VIII (damoctocog alfa pegol)